About | Free Trial

Last Update

2008-09-30T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Wrong A.P. Pharma?

A.P. Pharma

Vice President of Clinical Development, Vice President of Clinical Development

Financial News

HQ Phone: +44 20 7309 7704

Financial News

2Nd Floor Stapleton House 29-33 Scrutton Street

London EC2A 4HU

United Kingdom

Find other employees at this company (405)

Background Information

Employment History

Vice President Clinical Development, Actelion Pharmaceuticals, Senior Vice President Medical
J. Robert Scott

Affiliations

Board Member
A.P. Pharma Inc

Founder
Prescription Drug User Fee Act

Web References (200 Total References)


A.P. Pharma Announces ...

biz.yahoo.com, $reference.date [cached]

A.P. Pharma Announces Positive Phase 3 Results with APF530 in the Prevention of CINVA.P. Pharma Announces Positive Phase 3 Results with APF530 in the Prevention of CINV: Financial News - Yahoo! Finance

Yahoo!My Yahoo! Mail
...
A.P. Pharma Announces Positive Phase 3 Results with APF530 in the Prevention of CINV
...
Commenting on the results, Ronald Prentki, A.P. Pharma's President and CEO, stated, "We are highly encouraged with the results of our Phase 3 trial and are working diligently to get our product approved for marketing as soon as possible.
...
I would like to thank the clinical investigators and patients who participated in the study, and our employees who worked so hard over the past two years to complete the Phase 3 program, which is critical to the future of A.P. Pharma."
...
John Barr, Ph.D., A.P. Pharma's Senior Vice President of Research and Development, stated, "Importantly, these data with APF530 underscore the value of our Biochronomerâ„¢ drug delivery technology to improve the effectiveness of a drug.
...
Results released by A.P. Pharma are top-line data and the company is therefore unable to provide the level of detail and analysis that will be possible once the final safety and efficacy data become available and all additional sub-group analyses are completed.
...
A.P. Pharma's lead product, APF530, is being developed for the prevention of both acute and delayed onset CINV in patients receiving either moderately or highly emetogenic chemotherapy.
...
About A.P. Pharma
A.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems.


A.P. Pharma to Hold APF530 ...

biz.yahoo.com, $reference.date [cached]

A.P. Pharma to Hold APF530 Phase 3 Trial Results Conference Call September 30 at 9:00 a.m. EasternA.P. Pharma to Hold APF530 Phase 3 Trial Results Conference Call September 30 at 9:00 a.m. Eastern: Financial News - Yahoo! Finance

Yahoo!My Yahoo! Mail
...
A.P. Pharma to Hold APF530 Phase 3 Trial Results Conference Call September 30 at 9:00 a.m. Eastern
...
About A.P. Pharma
A.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems.
...
A.P. Pharma


A.P. Pharma to Hold 2008 ...

biz.yahoo.com, $reference.date [cached]

A.P. Pharma to Hold 2008 First Quarter Financial Results Conference Call May 15A.P. Pharma to Hold 2008 First Quarter Financial Results Conference Call May 15: Financial News - Yahoo! Finance

Yahoo!My Yahoo! Mail
...
A.P. Pharma to Hold 2008 First Quarter Financial Results Conference Call May 15
...
About A.P. Pharma
A.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems.


A.P. Pharma Announces Stock ...

biz.yahoo.com, $reference.date [cached]

A.P. Pharma Announces Stock Option GrantA.P. Pharma Announces Stock Option Grant: Financial News - Yahoo! Finance

Yahoo!My Yahoo! Mail
...
A.P. Pharma Announces Stock Option GrantWednesday January 16, 8:02 pm ET
REDWOOD CITY, Calif.--(BUSINESS WIRE)--A.P. Pharma, Inc. (NASDAQ:APPA - News), a specialty pharmaceuticals company, today announced it has made an option grant for 30,000 shares at an exercise price of $1.37 (the closing price as of the date of the grant) to a new employee, as an inducement to the individual entering into employment with the company, under the 2000 Non-Qualified Stock Option Plan.The options have a 10 year life and vest over a four year period.
About A.P. Pharma
A.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems.


A.P. Pharma Announces ...

biz.yahoo.com, $reference.date [cached]

A.P. Pharma Announces Executive Officer DepartureA.P. Pharma Announces Executive Officer Departure: Financial News - Yahoo! Finance

Yahoo!My Yahoo! Mail
...
A.P. Pharma Announces Executive Officer Departure
...
Mr. O'Connell originally joined A.P. Pharma in 1992 as Vice President and Chief Financial Officer.
...
About A.P. Pharma
A.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems.

Similar Profiles

Other People with this Name (1,139)

Other people with the name Pharma

Reva Pharma

Verona Pharma
Medicines Evaluation Unit

Neha Pharma
Trinau Inc

Lodaat Pharma
Live One Day At A Time

Lumos Pharma
Lumos Pharma , Inc.

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory